Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent.~2. Men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer~3. History of treatment by complete androgen blockade for greater than 3 months prior to enrollment~4. Progressive disease evidenced by 2 consecutive rises in PSA measured at least 1 week apart, with the absolute value of the latest PSA \> 5.0 ng/ml.~5. A rise in PSA following anti-androgen drug withdrawal, above the last PSA value before withdrawal.~6. Patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. Treatments indicated for HRPC are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-T.~Exclusion Criteria:~1. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.~2. Serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.~3. Patient weighs over 350 lbs (due to scanner weight limit).~4. Clinical life expectancy \< 12 weeks.~5. Participated in other radioactive drug studies where estimated total cumulative dose within 1 year is \> 0.05 Sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 Sievert for other organs.~6. Concurrent Therapy. Allowed: Prior or concurrent chemotherapy, but must be \> 12 weeks since last treatment at enrollment; prior or concurrent hormonal therapy; prior surgery; prior or concurrent bisphosphonate; prior or concurrent receptor/biologic agent allowed if given on approved study protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Received 18F-fluorocholine PET/CT (Type: EXPERIMENTAL): IV fluorine-18 labeled methylcholine before PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).